Amgen Does Not Expect Big Enbrel Price Impact From US Humira Biosimilar Launches

Q3 Revenue Down 1% But Beat Analyst Consensus

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Amgen will be first to launch a Humira biosimilar in the US with its Amgevita, but it and other adalimumab copies may add pressure to the company’s already declining top-seller Enbrel.

Sign from Amgen building in Switzerland
Amgen's $6.65bn in Q3 revenue beat consensus expectations of $6.57bn • Source: Shutterstock

Amgen, Inc. does not expect the launch of biosimilars for AbbVie Inc.’s TNF inhibitor Humira (adalimumab) to cause its own anti-TNF antibody and top-selling product Enbrel (etanercept) to experience net price declines in 2023 that are any more dramatic than the price cuts already implemented in 2022 to keep the product on payers’ formularies. And as the first company slated to launch a Humira biosimilar in the US, Amgen has a front seat to the competitive dynamics next year.

Amgevita, the company’s adalimumab biosimilar available in Europe, generated $117m in third quarter 2022 sales, up 5% from $111m in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Drug Pricing

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.